| bibliographicCitation |
Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, Chen J, Zhang H, Niu Z, Fan Q, Lin L, Gu K, Liu Y, Ba Y, Miao Z, Jiang X, Zeng M, Chen J, Fu Z, Gan L, Wang J, Zhan X, Liu T, Li Z, Shen L, Shu Y, Zhang T, Yang Q, Zou J, Luo S, Peng F, Wu G, Xu N, Zhao L, Ma D, Qin S, Ren W, Li E, Lu H, Pan Y, Xiong J, Yuan Y, Bai Y, Chen L, Hu Y, Zhang L, Gao Y. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. The Lancet Oncology. 2020 Jun;21(6):832–42. doi: 10.1016/s1470-2045(20)30110-8. |